W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Position of the Transparency Council

20 June, 2024

Position of the Transparency Council – specialized lactacion advice by a doctor and mildwife

20 June, 2024

Position of the Transparency Council – Vesoxx (oxybutynini hydrochloridum)

20 June, 2024

Position of the Transparency Council – Tecartus (brexucabtagene autoleucel)

24 August, 2022

Position of the Transparency Council – Milupa Basic-P

24 August, 2022

Position of the Transparency Council – Ospolot (sultiam)

24 August, 2022

Position of the Transparency Council – Jardiance (empagliflozyna)

24 August, 2022

Position of the Transparency Council – Yervoy (ipilimumab)

24 August, 2022

Position of the Transparency Council – Opdivo (niwolumab)

24 August, 2022

Position of the Transparency Council – Tremfya (guselkumabum)

16 August, 2022

Position of the Transparency Council – Inovelon (rufinamide)

16 August, 2022

Position of the Transparency Council – Fycompa (perampanel)

16 August, 2022

Position of the Transparency Council – Ozurdex (dexamethasone)

23 June, 2022

Position of the Transparency Council – qualifying the health care service “Care for families at high hereditary risk of retinoblastoma or von Hippel-Lindau (VHL) disease” as a guaranteed health care service

23 June, 2022

Position of the Transparency Council – qualifying the health care service “Colorectal cancer screening programme” as a guaranteed health care service

23 June, 2022

Position of the Transparency Council – qualifying the health care service “Care for families at high hereditary risk of breast or ovarian cancer” as a guaranteed health care service

23 June, 2022

Position of the Transparency Council – qualifying the health care service “Care for families at high hereditary risk of colorectal cancer or endometrial cancer” as a guaranteed health care service

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑